Yesterday, a Director at Aldeyra Therapeutics (ALDX), Martin Joseph Joyce, bought shares of ALDX for $9,962.
Following this transaction Martin Joseph Joyce’s holding in the company was increased by 9.47% to a total of $114.9K. In addition to Martin Joseph Joyce, 3 other ALDX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.70 and a one-year low of $4.31. Currently, Aldeyra Therapeutics has an average volume of 377.75K.
Starting in September 2018, ALDX received 30 Buy ratings in a row. Six different firms, including Canaccord Genuity and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on Aldeyra Therapeutics has been positive according to 12 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Martin Joseph Joyce’s trades have generated a 57.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes.
